Dr. Reddy's Laboratories, Incorporated

Msn Laboratories Private Limited

Msn Laboratories Private Limited, R&d Center

Rajesham Boge

Eswaraiah Sajja

Thirumalai Rajan Srinivasan

Vishweshwar Peddy

Rajeshwar Reddy Sagyam

Venkata Panakala Rao Gogulapati

Srividya Ramakrishnan

Javed Iqbal

Srinivas Oruganti

Rakeshwar Bandichhor

Deepika Pathivada

Sesha Reddy Yarraguntla

Amarnath Reddy Lekkala

Navin Vaya

Sundra Lakshmi Kanniah

Dharma Jagannadha Rao Velaga

Lalita Kanwar

Ramya Kumar

Ravi Kumar Mylavarapu

Sudhakar Reddy Baddam

Vagwala Raghunath

Anitha Naredla

Kiran Kumar Doniparthi

Lokeswara Rao Madivada

Mohammad Rafee Shaik

Yogesh S Gattani

Nagoji Shinde

Piyush Chudiwal

Rajesh Kumar Rapolu

Peddireddy Subbareddy

Chkradhar Nandigama

Pradip Kumar Ghosh

Sritharan Seetharaman

Srinivasa Rao Ambati

Vaibhav Sihorkar

Rajashekhar Totad

Krishna Venkatesh

Shyam Kiran Babu Gandham

Ganesh Arun Katkar

Snehalatha Movva

The present invention also relates to process for the preparation of N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-malate compound of formula-1a and its polymorphs thereof, represented by the following structural: 

Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof

The present invention relates to process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl] methyl]phenyl]-, (1S) formula-1 and its crystalline forms thereof. 

Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof

The present invention relates to a process for the preparation of Trisodium (4-{[(1S.3R)-1-([1,1'-biphenyl]-4-yl-methyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxo butanoate)-(N-pentanoyl-N-{[2&#x2032;-(1H-tetrazol-1-id-5-yl)[1,1&#x2032;-biphenyl]-4-yl]methyl}-L-valinate) represented by the following structural formula-1: 

Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2&#x2032;-(1H-tetrazol-1-1D-5-yl)[1,1&#x2032;-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof

The present invention relates to an improved process for the preparation of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) represented by the following structural formula: 

Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof

The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.

Crystalline forms of vilazodone hydrochloride and vilazodone free base

The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.

Enzalutamide polymorphic forms and its preparation

Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of &#x3b1; form crystal and &#x3b2; form crystal of mirabegron and pharmaceutical composition thereof.

Amorphous mirabegron and processes for crystal forms of mirabegron

Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of a form crystal and &#x3b2; form crystal of mirabegron and pharmaceutical composition thereof.

Aspects of the present disclosure include crystalline bazedoxifene free base, crystalline bazedoxifene acetate Form D, and processes for their preparation. The drug compound having the adopted name 'bazedoxifene acetate' has a chemical name 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid, and has the chemical structure shown below as Formula I. 

Preparation of crystalline bazedoxifene and its salts

Growing community of inventors

Hyderabad Telangana, India

Rajesham Boge